US proposes schedule II restrictions for J&J's analgesic tapentadol
This article was originally published in Scrip
Executive Summary
The US Drug Enforcement Administration (DEA) has proposed classifying Johnson & Johnson's immediate-release oral analgesic tapentadol as a schedule II controlled substance.